These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 20007955)

  • 61. [Treatment of servere ulcerative colitis].
    Weersma RK; van Dullemen HM; Kleibeuker JH; Ploeg RJ; Dijkstra G
    Ned Tijdschr Geneeskd; 2006 Jan; 150(1):12-7. PubMed ID: 16440618
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Anti-TNF-alpha antibody treatment of patients with active ulcerative colitis].
    Ainsworth MA; Brynskov J
    Ugeskr Laeger; 2007 Feb; 169(9):789-91. PubMed ID: 17355841
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comment on the comment of Dr. Daniel Present.
    Chey WY; Shah AN
    Am J Gastroenterol; 2002 Apr; 97(4):1066. PubMed ID: 12003395
    [No Abstract]   [Full Text] [Related]  

  • 64. Management of refractory fistulizing pouchitis with infliximab.
    Viscido A; Kohn A; Papi C; Caprilli R
    Eur Rev Med Pharmacol Sci; 2004; 8(5):239-46. PubMed ID: 15638238
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Biologics treatment for ulcerative colitis].
    Nagahori M; Fujii T; Saito E; Ohtsuka K; Watanabe M
    Nihon Shokakibyo Gakkai Zasshi; 2013 Nov; 110(11):1909-15. PubMed ID: 24189818
    [No Abstract]   [Full Text] [Related]  

  • 66. [Inflammatory diseases of the intestines].
    Felley C; Guyot J; Hess J; Mottet C; Delarive J; Michetti P
    Rev Med Suisse; 2006 Jan; 2(49):191-4, 196-8, 201-3. PubMed ID: 16493962
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Letter: The effects of preoperative infliximab on complications after surgery for ulcerative colitis.
    Yamamoto T
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1106-7; author reply 1107-8. PubMed ID: 23130779
    [No Abstract]   [Full Text] [Related]  

  • 68. [Use of infliximab in ulcerative colitis].
    Tilg H; Feichtenschlager T; Knoflach P; Petritsch W; Schöfl R; Vogelsang H; Reinisch W
    Z Gastroenterol; 2007 Aug; 45(8):907-11. PubMed ID: 17701864
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Using Therapeutic Drug Monitoring to Identify Variable Infliximab Metabolism in an Individual Patient With Ulcerative Colitis.
    Stein BN; Pellish RS; Thompson KD; Baptista V; Siegel CA
    J Clin Gastroenterol; 2016 Jan; 50(1):66-8. PubMed ID: 26191643
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Emerging biologic therapies in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(2):66-85. PubMed ID: 15184826
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.
    Fasanmade AA; Adedokun OJ; Olson A; Strauss R; Davis HM
    Int J Clin Pharmacol Ther; 2010 May; 48(5):297-308. PubMed ID: 20420786
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment of experimental ulcerative colitis.
    Lazebnik LB; Lychkova AE; Knyazev OV
    Bull Exp Biol Med; 2012 Oct; 153(6):889-92. PubMed ID: 23113311
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ulcerative colitis is not a rare complication of Takayasu arteritis.
    Watanabe R; Ishii T; Nakamura K; Shirai T; Fujii H; Saito S; Harigae H
    Mod Rheumatol; 2014 Mar; 24(2):372-3. PubMed ID: 24593217
    [No Abstract]   [Full Text] [Related]  

  • 74. Appendicectomy as a potential therapy for refractory ulcerative proctitis.
    Bageacu S; Coatmeur O; Lemaitre JP; Lointier P; Del Tedesco E; Phelip JM; Roblin X
    Aliment Pharmacol Ther; 2011 Jul; 34(2):257-8. PubMed ID: 21679209
    [No Abstract]   [Full Text] [Related]  

  • 75. Comparison of Immunoassays for Measuring Serum Levels of Golimumab and Antibodies Against Golimumab in Ulcerative Colitis: A Retrospective Observational Study.
    Berger AE; Duru G; de Vries A; Marini JC; Aoucheta D; Cornillie F; Nancey S; Detrez I; Gils A; Roblin X; Paul S
    Ther Drug Monit; 2019 Aug; 41(4):459-466. PubMed ID: 30817702
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The market for ulcerative colitis.
    Al-Horani R; Spanudakis E; Hamad B
    Nat Rev Drug Discov; 2022 Jan; 21(1):15-16. PubMed ID: 34815547
    [No Abstract]   [Full Text] [Related]  

  • 77. Editorial: infliximab trough levels and histological healing in ulcerative colitis-a step towards personalised biologic therapy.
    Lobaton T; De Vos M
    Aliment Pharmacol Ther; 2018 Mar; 47(6):855-856. PubMed ID: 29446129
    [No Abstract]   [Full Text] [Related]  

  • 78. Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases.
    Paintaud G; Passot C; Ternant D; Bertolotto A; Bejan-Angoulvant T; Pascual-Salcedo D; Mulleman D
    Ther Drug Monit; 2017 Aug; 39(4):339-343. PubMed ID: 28486309
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Therapeutic Drug Monitoring for Immune-Mediated Inflammatory Diseases.
    Wallace ZS; Sparks JA
    JAMA; 2021 Dec; 326(23):2370-2372. PubMed ID: 34932096
    [No Abstract]   [Full Text] [Related]  

  • 80. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.